Safety and immunogenicity of a novel therapeutic DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in normal rats.

The pathogenesis of rheumatoid arthritis. N Engl J Med (2011) 12.16

Regulatory T cells and mechanisms of immune system control. Nat Med (2004) 4.23

Effects of oral administration of type II collagen on rheumatoid arthritis. Science (1993) 3.32

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis (2014) 2.24

Collagens and collagen-related diseases. Ann Med (2001) 1.98

Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol (2003) 1.87

Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 1.65

A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis. Arthritis Res Ther (2009) 1.65

Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur J Immunol (1999) 1.35

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis (2014) 1.31

Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Arthritis Rheumatol (2014) 1.21

T cell epitopes of type II collagen that regulate murine collagen-induced arthritis. J Immunol (1993) 1.16

The role of collagen antibodies in mediating arthritis. Mod Rheumatol (2008) 1.13

Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther (2011) 1.12

Autoimmune priming, tissue attack and chronic inflammation - the three stages of rheumatoid arthritis. Eur J Immunol (2014) 1.02

TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep (2012) 0.99

Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis. Clin Ther (2013) 0.98

TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis. Ann Rheum Dis (2003) 0.95

Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+CD25+ Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Biomed Pharmacother (2010) 0.91

A novel recombinant peptide containing only two T-cell tolerance epitopes of chicken type II collagen that suppresses collagen-induced arthritis. Mol Immunol (2008) 0.87

Characterization of recombinant type II collagen: arthritogenicity and tolerogenicity in DBA/1 mice. Immunology (1998) 0.86

Construction and characterization of a novel DNA vaccine that is potent antigen-specific tolerizing therapy for experimental arthritis by increasing CD4+CD25+Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Vaccine (2008) 0.83

Potent antirheumatic activity of a new DNA vaccine targeted to B7-2/CD28 costimulatory signaling pathway in autoimmune arthritis. Hum Gene Ther (2010) 0.82

Targeting TNF-alpha with a tetravalent mini-antibody TNF-TeAb. Biochem J (2007) 0.80

Potent control of acute graft-versus-host disease lethality after immunization with a novel DNA vaccine targeted to B7-1/CD28 costimulatory signaling pathway. J Immunother (2013) 0.80

Vaccines based on structure-based design provide protection against infectious diseases. Expert Rev Vaccines (2013) 0.79

Evaluation of humoral and cellular immune responses to a DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in normal rats. Hum Vaccin Immunother (2015) 0.78